Zentalis Pharmaceuticals, Inc. Earnings Per Share Disclosure
| Year ended December 31, | |||||||||||||||||
| 2024 | 2023 | 2022 | |||||||||||||||
| Numerator: | |||||||||||||||||
| Net loss attributable to Zentalis | $ | (165,839) | $ | (292,191) | $ | (236,806) | |||||||||||
| Denominator: | |||||||||||||||||
| Weighted average number of common shares outstanding, basic and diluted | 71,080 | 65,409 | 52,857 | ||||||||||||||
| Net loss per common share | $ | (2.33) | $ | (4.47) | $ | (4.48) | |||||||||||
| Year ended December 31, | |||||||||||||||||
| 2024 | 2023 | 2022 | |||||||||||||||
| Outstanding stock options | 13,369 | 10,017 | 8,051 | ||||||||||||||
| Unvested RSAs | — | 1 | 126 | ||||||||||||||
| Unvested RSUs | 2,074 | 1,219 | 923 | ||||||||||||||
| 15,443 | 11,237 | 9,100 | |||||||||||||||
Want the next Zentalis Pharmaceuticals, Inc. earnings per share disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Zentalis Pharmaceuticals, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2024 | Mar 26, 2025 | Showing above |
| 2021 | Feb 24, 2022 | |
| 2020 | Mar 25, 2021 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.